Syndax Pharmaceuticals
SNDX
218 hedge funds and large institutions have $1.24B invested in Syndax Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 87 increasing their positions, 63 reducing their positions, and 26 closing their positions.
129% more call options, than puts
Call options by funds: $18.1M | Put options by funds: $7.88M
38% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 63
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
3.43% more ownership
Funds ownership: 115.2% → 118.64% (+3.4%)
1% more funds holding
Funds holding: 215 → 218 (+3)
4% less capital invested
Capital invested by funds: $1.3B → $1.24B (-$55.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$54.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$37M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$25.7M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$59.2M |
| 2 |
Morgan Stanley
New York
|
-$42.7M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$30.1M |
| 4 |
Goldman Sachs
New York
|
-$28.6M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$23.6M |
SNDX Hedge Fund Activity: Q1 2025 in Review
218 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2025, worth a combined $1.24B — down 4.3% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SNDX positions and 26 closed out — a net gain of 5 holders — while 87 added to existing stakes and 63 trimmed.
The largest buyer was Eversept Partners, adding an estimated $54.6M. The largest seller was Wellington Management Group, cutting an estimated $59.2M.
- 218 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2025, up from 215 in Q4 2024.
- Funds reported $1.24B of Syndax Pharmaceuticals stock for Q1 2025, down 4.3% quarter-over-quarter.
- 31 funds opened new Syndax Pharmaceuticals positions in Q1 2025 and 26 closed out, a net change of +5 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2025 was Eversept Partners, an estimated $54.6M added.
- The largest Syndax Pharmaceuticals seller in Q1 2025 was Wellington Management Group, an estimated $59.2M sold.
Based on aggregated 13F filings for Q1 2025.